Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses.

Lee K, Overwijk WW, O'Toole M, Swiniarski H, Restifo NP, Dorner AJ, Wolf SF, Sturmhoefel K.

J Interferon Cytokine Res. 2000 Jun;20(6):589-96.

2.

Cytokines and cancer immunotherapy.

Wolf SF, Lee K, Swiniarski H, O'Toole M, Sturmhoefel K.

Immunol Invest. 2000 May;29(2):143-6. Review. No abstract available.

PMID:
10854183
3.

IL-12-Dependent enhancement of CTL response to weak class I-restricted peptide immunogens requires coimmunization with T helper cell immunogens.

Swiniarski H, Wolf SF, Sturmhoefel K, Peterson RL, Dorner AJ, O'Toole M.

Clin Immunol. 2000 Mar;94(3):200-11.

PMID:
10692239
4.

A CTL assay requiring only 150 microliter of mouse blood.

Swiniarski H, Sturmhoefel K, Lee K, Wolf SF, Dorner AJ, O'Toole M.

J Immunol Methods. 2000 Jan 13;233(1-2):1-11.

PMID:
10648850
5.

Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.

Sturmhoefel K, Lee K, Gray GS, Thomas J, Zollner R, O'Toole M, Swiniarski H, Dorner A, Wolf SF.

Cancer Res. 1999 Oct 1;59(19):4964-72.

6.

Immune response enhancement by in vivo administration of B7.2Ig, a soluble costimulatory protein.

Swiniarski H, Sturmhoefel K, Lee K, Gray GS, Thomas JL, Wolf SF, Dorner AJ, O'Toole M.

Clin Immunol. 1999 Sep;92(3):235-45.

PMID:
10479528
7.

B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.

Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K, Lee K, Wolf S, Gajewski TF, Fitch FW.

J Immunol. 1998 Nov 15;161(10):5268-75.

Supplemental Content

Loading ...
Support Center